Global Tuberculosis Pipeline 2016 Market Report on 64 Companies
PUNE, India, June 17, 2016 /PRNewswire/ --
ReportsnReports.com adds "Tuberculosis - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, Tuberculosis therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Tuberculosis with 109 market data tables and 17 figures, spread across 399 pages is available at http://www.reportsnreports.com/reports/594608-tuberculosis-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Tuberculosis Pipeline Review, H1 2016 report include Abera Bioscience AB, Achillion Pharmaceuticals, Inc., Alvogen Korea Co., Ltd., Anacor Pharmaceuticals, Inc., Archivel Farma S.L., AstraZeneca Plc, Bayer AG, BioDiem Ltd, BioLingus AG, Biomar Microbial Technologies, Bioversys AG, Celgene Corporation, Cellceutix Corporation, Chongqing Zhifei Biological Products Co., Ltd., Dafra Pharma International Ltd., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, Ensol Biosciences Inc., EpiVax, Inc., FIT Biotech Oy, GangaGen Inc., GlaxoSmithKline Plc, Globeimmune, Inc., Hager Biosciences, LLC, Hsiri Therapeutics, LLC, Imaxio SA, Immunitor, Inc., ImmunoBiology Limited, Immunovaccine, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Lipotek Pty Ltd., Matinas BioPharma Holdings, Inc., Microbion Corporation, Microbiotix, Inc., NEARMEDIC PLUS, Ltd, Novartis AG, NovoBiotic Pharmaceuticals, LLC, Otsuka Holdings Co., Ltd., Polymun Scientific Immunbiologische Forschung GmbH, Prokarium Limited, QureTech Bio AB, Recce Limited, Rodos BioTarget GmbH, Sanofi, Sanofi Pasteur SA, Sarepta Therapeutics, Inc., SEEK Group, Sequella, Inc., Shionogi & Co., Ltd., Sphaera Pharma Pvt. Ltd., Spring Bank Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TetraLogic Pharmaceuticals, Theravectys SA, Tomegavax, Inc., Transgene SA, TVAX Biomedical, Inc., Univalue Valorizacion, S.L., Vaccibody AS, Vakzine Projekt Management GmbH, Vaxil Bio Therapeutics Ltd., Vertex Pharmaceuticals Incorporated and Vichem Chemie Research Ltd.
Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=594608 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Tuberculosis and reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Tuberculosis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Tuberculosis.
Another newly published market research report titled on Muscular Dystrophy - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. Companies discussed in this research are Acceleron Pharma, Inc., AMO Pharma Limited, Asahi Kasei Pharma Corp., aTyr Pharma, Inc., Benitec Biopharma Limited, Bioblast Pharma Ltd., BioMarin Pharmaceutical Inc., Biophytis SAS, Evotec AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Genethon, Ionis Pharmaceuticals, Inc., Marina Biotech, Inc., Novogen Limited, Prothelia, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Selecta Biosciences, Inc., Takeda Pharmaceutical Company Limited and WAVE Life Sciences Ltd. Muscular Dystrophy Pipeline market research report of 113 pages is available at http://www.reportsnreports.com/reports/594616-muscular-dystrophy-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. +1 888 391 5441 email@example.com